Panagiotis J. Vlachostergios

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling

Brian D. Robinson, Panagiotis J. Vlachostergios, Bhavneet Bhinder et al. · Nature Communications · 2019 · 212 citations · Full text

Medicine, Cancer Biology, Urology +17

<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors

Emmanuel S. Antonarakis, Pedro Isaacsson Velho, Wei Fu et al. · JCO Precision Oncology · 2020 · 206 citations · Full text

Medicine, Oncology, Pathology +17

Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

Christina Befani, Panagiotis J. Vlachostergios, Eleana Hatzidaki et al. · Journal of Molecular Medicine · 2011 · 133 citations

Medicine, Molecular Biology, Oncology +17

Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis

Ioannis Gioulbasanis, Panagiotis Georgoulias, Panagiotis J. Vlachostergios et al. · Lung Cancer · 2011 · 85 citations

Agriculture, Nutritional Sciences, Oncology +16

SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy

Vincenza Conteduca, Sheng‐Yu Ku, Loredana Puca et al. · Molecular Cancer Therapeutics · 2020 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17